Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 5:27 AM

Centocor Inc

Type: Company
Name: Centocor Inc
Nationality: United States
First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents (in Biology)
Ustekinumab (Stelara–Centocor Ortho Biotech)
If a serious infection occurs, ustekinumab should be discontinued until the infection resolves.All patients should be evaluated for tuberculosis (TB) before initiating treatment with ustekinumab. Patients with active TB should not be started on ustekinumab. ... [Pharmacist.com - 11/19/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 2 Documents (in Politics)
The Nielsen Company - Click to view 360-page
The Nielsen Company
Nielsen Announces 2009 Winners of the First-Ever CLIO Healthcare Awards
NEW YORK, Nov. 16 /PRNewswire/ The Nielsen Company, a leading global information and media company and the CLIO Awards, one of the world's most recognized international advertising and design competitions, today announced the winners of the first-ever ... [Pharmacy Choice - 11/17/2009]
First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents (in Intellectual Property Rights)
Abbott Laboratories Inc - Click to view image in its original context
Abbott Laboratories Inc
Patently-O Bits and Bytes: New Job Openings
Patent Prosecutor - Law Firm - Woodbridge, N.J.Patent Counsel - Small Corporation - Cambridge, Mass.Patent Attorney (Prosecution) - Law Firm - Alexandria, Va.Sr. Intellectual Property Counsel - Law Firm - Boston, Mass.Patent Agent/Associate - Law Firm ... [Patent Law Blog (Patently-O) - 11/16/2009]
First Reported 10/28/2009 - Updated 10/28/2009 - 5 Documents (in Internet & IT)
Morphotek, Centocor Enter Antibody Licensing Deal
Morphotek, Inc. has entered into a license agreement with for the development and commercialization of an antibody targeting solid tumors. Financial terms were not disclosed.Morphotek has been granted an exclusive worldwide license for the development, ... [Contract Pharma - 10/28/2009]
First Reported 10/29/2009 - Updated 10/29/2009 - 2 Documents (in Biology)
Morphotek gets license to Centocor's antibody for cancer
Morphotek has secured an exclusive worldwide license to develop and commercialize Centocor Ortho Biotech's antibody that homes in on an antigen that is overexpressed in various solid tumors. Centocor has subjected the antibody to preclinical trials.American ... [SmartBrief - 10/29/2009]
First Reported 11/03/2009 - Updated 11/03/2009 - 2 Documents (in Corporate Deals)
Schering Plough Corporation - Click to view 360-page
Schering Plough Corporation
Merck/Schering-Plough merger complete
Philadelphia Business Journal - by John George Staff WriterJohnson & Johnson files to end Schering-Plough relationshipFDA approves GlaxoSmithKline’s CervarixNew class of HIV/AIDS drugs works faster in trialWhat Merck post-Schering Plough merger will look ... [Philadelphia Business Journal - 11/03/2009]
First Reported 10/22/2009 - Updated 10/23/2009 - 2 Documents
Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for ... [News-Medical.Net - 10/23/2009]
First Reported 10/27/2009 - Updated 10/27/2009 - 1 Documents (in Medicine)
Centocor Ortho Biotech
Name of campaign: “Live in My Skin”Creative credits: Creative director and director: Tim Hawkey; art directors: Carl Affarian, Jeff Yates; copywriter: Peri Silverman; producer:Rated Rx; account executive: Talin ApkarianWhy we liked it: Starting with the ... [BToBOnline - 10/27/2009]
First Reported 10/28/2009 - Updated 10/28/2009 - 1 Documents
TNF-Alpha Inhibitors Will Continue to Dominate First- and Second-Line Biologic Therapy for the Treatment of Rheumatoid Arthritis Through 2011
However, TNF-Alpha Inhibitors Are Not Immune to Competition From Roche's Emerging IL-6 Inhibitor Actemra, According to a New Report from Decision Resources Patient-Flow Models Will Need to Take Into Account That Over Ten Percent of Patients Starting Humira ... [PR Newswire - 10/28/2009]
First Reported 11/04/2009 - Updated 11/04/2009 - 1 Documents (in Corporate Deals)
Johnson & Johnson: The Elephant in the Merck-Schering Living Room
As Merck & Co (MRK) starts a new chapter Wednesday following its $41 billion acquisition, sorry, reverse merger, of Schering-Plough (SGP), the elephant in the room remains the ongoing arbitration with Johnson & Johnson (JNJ) over two of Scherings most ... [Seeking Alpha - 11/04/2009]
First Reported 11/06/2009 - Updated 11/06/2009 - 1 Documents (in Conflicts & Crime)
The Am Law Litigation Daily -- Nov. 6, 2009
Posted by Alison FrankelLitigator of the WeekJeffrey Chanin of Keker & Van NestJeffrey Chanin was full of praise for the highly educated California state court jury that delivered a win for his client, Taiwan Semiconductor, in a trade secrets case against ... [The American Lawyer - 11/06/2009]
First Reported 11/07/2009 - Updated 11/07/2009 - 1 Documents (in Conflicts & Crime)
Federal Court Upholds $1.7 Billion Patent Award to Centocor
In a victory for Centocor Ortho Biotech, a district court has upheld the company’s $1.7 billion jury award for Abbott Laboratories’ infringementon its Humira patent. ... [FDA News - 11/07/2009]

More Content

All (126) | News (115) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (2)
sort by: Date | Relevance
Focus on 2009: A year of novel pharmacologic ag... [Modern Medicine - 12 hours ago]
Ustekinumab (Stelara–Centocor Ortho Biotech) [Pharmacist.com - 11/19/2009]
'Wear Ur SPF' Text Reminders Increase Sunscreen... [MedPage Today - 11/17/2009]
Research and Markets: Dealmaking and Industry O... [RBC Dain Rauscher - 11/17/2009]
Nielsen Announces 2009 Winners of the First-Eve... [Pharmacy Choice - 11/17/2009]
IA: Iowa will recover $1.2 milli... [Stateline - 11/17/2009]
Nielsen Announces 2009 Winners of the First-Eve... [ShootOnline - 11/17/2009]
R U Robot Ready? [Pharmacy Practice News - 11/16/2009]
Nielsen Announces 2009 Winners of the First-Eve... [PR Newswire - 11/16/2009]
R U Robot Ready?... [Pharmacy Practice News - 11/16/2009]
Stelara, first IL inhibitor, expected to change... [News-Medical.Net - 11/12/2009]
Decision Resources: Biosimilars may cause biote... [Drug Store News - 11/11/2009]
Federal court upholds $1.7 billion patent award... [Drug Store News - 11/11/2009]
Roche Basel's MAB95 Facility Named 2009 Facilit... [PharmaceuticalProcessing - 11/11/2009]
Morphotek Signs a Pact with Centocor for a Ther... [BioPharm International - 11/11/2009]
Five Prime Therapeutics, Inc. to Present at Laz... [RBC Dain Rauscher - 11/11/2009]
ODAC Vote Against Yondelis Dissected... [Pharmacy Practice News - 11/10/2009]
Using surveys and other approaches for determin... [Cambridge Network - 11/10/2009]
Pfizer to cut jobs at Wyeth's Montco site [Philadelphia Inquirer - 11/10/2009]
Clopidogrel Benefit Roughly Equal for Women and... [MedPage Today - 11/09/2009]
J&J to cut 174 Montco jobs [Philadelphia Inquirer - 11/09/2009]
Federal Court Upholds $1.7 Billion Patent Award... [FDA News - 11/07/2009]
The Am Law Litigation Daily -- Nov. 6, 2009 [The American Lawyer - 11/06/2009]
Company and People Notes: Eli Lilly opens biote... [Pharmaceutical Technology - 11/05/2009]
Johnson & Johnson: The Elephant in the Merc... [Seeking Alpha - 11/04/2009]
TNF-alpha inhibitors ranked top for reducing bi... [News-Medical.Net - 11/04/2009]
Merck/Schering-Plough merger complete [Philadelphia Business Journal - 11/03/2009]
Merck/Schering-Plough merger complete [Biz Journals - 11/03/2009]
Crohn's disease drug market driven by TNF-alpha... [News-Medical.Net - 11/03/2009]
And the Award goes to.... [Medical Marketing And Media - 11/01/2009]
1 2 3 4
In Focus
  •  
Robert Franc, Caren Cowhig, Brian Kenney, [more]
  •  
Abbott Laboratories Inc, Johnson & Johnson, Schering Plough Corporation, [more]
  •  
Food and Drug Administration, New York University, Health Canada, [more]
  •  
SIMPONI, Biotechnology, Antibody, [more]
  •  
Malvern (Pennsylvania, United States), Exton (United States), Philadelphia (Pennsylvania, United St ..., [more]
  •  
United States, Ireland, Japan, [more]
  •  
Medicine, Biotechnology, Biology, [more]
  •  
Pharma & Biotech, Health, Media & Advertising, [more]
PharmaBiz, Pharmaceutical Business Review, Patent Law Blog (Patently-O), [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Patently-O Bits and Bytes: New Job Openings [Patent Law Blog (Patently-O) - 11/16/2009]
Patent Prosecutor - Law Firm - Woodbridge, N.J.Patent Counsel - Small Corporation - Cambridge, Mass.Patent Attorney (Prosecution) - Law Firm - Alexandria, Va.Sr. ...
Centocor v. Abbott (E.D.Tex.) [Patent Law Blog (Patently-O) - 07/24/2009]
Centocor v. Abbott (E.D.Tex.)Abbott has two chances to block the $1.67 billion jury verdict while the case is still in the hands of E.D. Texas Judge Ward.Inequitable ...
A Singular Verdict From the Lone Star State [WSJ.com: Law Blog - 06/30/2009]
While much of the legal world had its eyes trained either on all-things Madoff or all-things Scotus on Monday, the attention of two groups of lawyers down in Marshall, ...
Centocor v. Abbott: $1.67 Billion Jury Verdict [Patent Law Blog (Patently-O) - 06/30/2009]
Centocor (Johnson & Johnson) & NYU v. Abbott Labs (E.D.Tex. 2009)In what may be the largest patent jury verdict in US history, an Eastern District of Texas jury ...
Financing Activity May Lift Cloud Hanging over ... [Biotech Sector and Stocks Analysis from Seeking ... - 05/26/2009]
The Burrill Report submits: By MARIE DAGHLIANAlthough investors are grasping at any positive sign of improvement in the economy to push a market rally forward, the ...
1 2

  •  
  •  
  •